Chronic Exendin-4 Treatment Prevents the Development of Cancer Cachexia Symptoms in Male Rats Bearing the Yoshida Sarcoma

Hormones and Cancer

Volumn 5, Issue 1, 2014, Pages 33-41

  Honors, Mary Ann ^a   Kinzig, Kimberly P ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; CONTROLLED STUDY; DRUG MECHANISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; YOSHIDA SARCOMA;

ANIMALS; CACHEXIA; CARCINOGENESIS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; INSULIN RESISTANCE; MALE; NEOPLASM TRANSPLANTATION; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SARCOMA, YOSHIDA; TUMOR BURDEN; VENOMS;

EID: 84892455063     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0163-9     Document Type: Article

References (52)

1. Asp ML, Tian M, Wendel AA, Belury MA (2010) Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer 126.
2. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 27.
3. Baracos VE (2002) Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care 5: 3.
4. Chaudhuri A, Ghanim H, Vora N, Sia CL, Korzeniewski K, Dhindsa S, Makdissi A, Dandona P (2012) Exenatide exerts a potent anti-inflammatory effect. J Clin Endocrinol Metab 97(1): 10.
5. Copeland GP, Al-Sumidaie AM, Leinster SJ, Davis JC, Hipkin LH (1987) Glucose metabolism in patients with gastrointestinal malignancy but without excessive weight loss. Eur J Surg Oncol 13(1): 6.
6. Copeland GP, Leinster SJ, Davis JC, Hipkin LJ (1987) Insulin resistance in patients with colorectal cancer. Br J Surg 74(11): 5.
7. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity, and diabetes. Trends Immunol 25(1): 4-8.
8. Davidson JA (2009) Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 76: 11.
9. el Razi Neto S, Zorn TMT, Curi R, Carpinelli AR (1996) Impairment of insulin secretion in pancreatic islets isolated from Walker 256 tumor-bearing rats. Am J Physiol Cell Physiol 271: 5.
10. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A et al (2008) Cachexia: a new definition. Clin Nutr 27: 793-799.
11. Fernandes LC, Carpinelli AR, Hell NS, Curi R (1991) Improvement of cancer cachexia and decrease of Walker 256 tumor growth by insulin administration in rats. Cancer Ther Control 1(10).
12. Fernandes LC, Curi R (1997) Reversion of Walker 256 tumor cachexia by insulin treatment: possible mechanisms involved and perspectives for future research. Endocr Relat Cancer 4: 465-474.
13. Fernandes LC, Machado UF, Nogueira CR, Carpinelli AR, Curi R (1990) Insulin secretion in Walker 256 tumor cachexia. Am J Physiol Endocrinol Metab 258.
14. Glickman AS, Rawson RW (1956) Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer 9.
15. Gordon JN, Green SR, Goggin PM (2005) Cancer cachexia. Q J Med 98: 10.
16. Guaitani A, Recchia M, Carli M, Rocchetti M, Bartosek I, Garattini S (1982) Walker carcinoma 256: a model for studies on tumor-induced anorexia and cachexia. Oncology 39: 6.
17. Han VK, Hynes MA, Jin C, Towle AC, Lauder JM, Lund PK (1986) Cellular localization of proglucagon/glucagon-like peptide messenger RNAs in the rat brain. J Neurosci Res 16: 11.
18. Heller C, Kuhn MC, Mulders-Opgenoorth B, Schott M, Willenberg HS, Scherbaum WA, Schinner S (2011) Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic beta-cell proliferation. Am J Physiol Endocrinol Metab 301: 9.
19. Hofbauer KG, Anker SD, Inui A, Nicholson JR (2006) Pharmacotherapy of cachexia. CRC, Boca Raton.
20. Holroyde CP, Reichard GA (1981) Carbohydrate metabolism in cancer cachexia. Cancer Treat Rep 65: 5.
21. Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reichard GA (1975) Altered glucose metabolism in metastatic cancer. Cancer Res 35: 5.
22. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 31.
23. Honors MA, Kinzig KP (2012) The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachex Sarcopenia Muscle 3: 7.
24. Honors MA, Kinzig KP (2013) Characterization of the Yoshida sarcoma: a model of cancer cachexia. Support Care Cancer. doi: 10. 1007/s00520-013-1839-y.
25. Idris I, Patiag D, Gray S, Donnelly R (2002) Exendin-4 increases insulin sensitivty via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem Pharmacol 63: 4.
26. Jasani B, Donaldson LJ, Ratcliffe JG, Sokhi GS (1978) Mechanism of impaired glucose tolerance in patients with neoplasia. Br J Cancer 38: 6.
27. Koehler JA, Drucker DJ (2006) Activation of glucagon-like peptide-1 receptor signaling does not modify growth or apoptosis of human pancreatic cancer cells. Diabetes 55: 11.
28. Koehler JA, Kain T, Drucker DJ (2011) Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology 152(9): 11.
29. Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B, Huang JQ, Pierce JW (1999) A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am J Physiol Endocrinol Metab 277.
30. Lazarus DD, Kambayashi T, Lowry SF, Strassmann G (1996) The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-26-mediated cancer cachexia. Cancer Lett 103: 7.
31. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE (2004) Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 15.
32. Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T (2012) The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat 132: 449-461.
33. Lundholm K, Holm G, Schersten Y (1978) Insulin resistance in patients with cancer. Cancer Res 38: 6.
34. Lundholm K, Korner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, Bosaeus I (2007) Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 13(9): 8.
35. Matthys P, Billiau A (1997) Cytokines and cachexia. Nutrition 13(9): 763-770.
36. McCarthy HD, McKibbin PE, Perkins AV, Linton EA, Williams G (1993) Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats. Am J Physiol Endocrinol Metab 264: 6.
37. Moley JF, Morisson SD, Norton JA (1985) Insulin reversal of cancer cachexia. Cancer Res 45: 7.
38. Moley JF, Morrison SD, Gorschboth CM, Norton JA (1988) Body composition changes in rats with experimental cancer cachexia: improvement with exogenous insulin. Cancer Res 48: 4.
39. Nelson D, Ganss R (2006) Tumor growth or regression: powered by inflammation. J Leukoc Biol 80: 6.
40. Nixon JP, Zhang M, Wang C, Kuskowski M, Novak CM, Levine JA, Billington CJ, Kotz CM (2010) Evaluation of a quantitative magnetic resonance imaging system for whole body composition analysis in rodents. Obesity 18(8): 1652-1659.
41. Norton JA, Maher M, Wesley R, White D, Brennan MF (1984) Glucose intolerance in sarcoma patients. Cancer 54: 6.
42. Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP (1993) Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 11: 8.
43. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9): 6.
44. Pollak M (2008) Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8: 14.
45. Schein PS, Kisner D, Haller D, Blecher M, Hamosh M (1979) Cachexia of malignancy: potential role of insulin in nutritional management. Cancer 43: 8.
46. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I, Ishitsuka H, Kataoka T (1990) Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50: 6.
47. Tayek JA (1992) A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 11: 12.
48. Temparis S, Asensi M, Taillandier D, Aurousseau E, Larbaud D, Obled A, Bechet D, Ferrara M, Estrela JM, Attaix D (1994) Increased ATP-ubiquitin-dependent proteolysis in skeletal muscle of tumor-bearing rats. Cancer Res 54: 6.
49. Teunissen CC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag 34(1): 11.
50. Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2: 10.
51. Tomayko MM, Patrick Reynolds C (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 7.
52. Wang A, Hu Z, Hu J, Du J, Mitch WE (2006) Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 147: 9.